Medtronic (NYSE:MDT) announced that it completed the first patient implants in the Titan 2 pivotal study of its investigational neuromodulation device.
Fridley, Minnesota-based Medtronic’s Titan 2 trial will evaluate the safety and efficacy of the company’s implantable tibial neuromodulation (TNM) device in people with overactive bladder (OAB).